Atrial fibrillation (AF) is a documented risk factor for dementia. However, it is unclear whether
oral anticoagulant (OAC) treatment can reduce the development of dementia or cognitive …

Atrial fibrillation is a common disease of the elderly, conferring considerable morbidity and
mortality related to cardiovascular effects and thromboembolic risks. Anticoagulation …

Background Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism
and mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may …

The direct oral anticoagulants (DOACs) are drugs used in clinical practice since 2009 for the
prevention of stroke or systemic embolism in non-valvular atrial fibrillation, and for the …

Introduction Guidelines recommend the assessment of stroke and bleeding risk before
initiating warfarin anticoagulation in patients with atrial fibrillation. Many of the elements …

Non-valvular atrial fibrillation (NVAF) represents a major health-care problem, needing an
extensive and strict thrombosis prevention for stroke and cardiovascular (CV) disease risks …

Aims History of bleeding strongly influences decisions for anticoagulation in atrial fibrillation
(AF). We analyzed outcomes in relation to history of bleeding and randomization in …

Direct oral anticoagulants (DOACs), direct inhibitors of thrombin or factor Xa (FXa), are
increasingly used in clinical practice for the prevention of thromboembolic complications in …

Background Current guidelines recommend vitamin K antagonists (VKAs) or non-vitamin K
antagonist oral anticoagulants (NOACs) for stroke prevention in patients with non-valvular …

Atrial fibrillation (AF) is the most common sustained cardiac dysrhythmia, and is associated
with an increased risk of death, stroke, and other thromboembolic events. Valvular heart …